Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD70-directed CAR-NK cells with IL-15
- Development stage
- Preclinical
- Lead developer
- Bio-Techne
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD70-directed CAR-NK cells with IL-15 is an allogeneic, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy engineered to target the CD70 antigen. The therapy utilizes NK cells modified via the non-viral TC Buster transposon system to express a CAR specific for CD70 and an Interleukin-15 (IL-15) expression cassette, which enhances the persistence, proliferation, and cytotoxic activity of the cells. To prevent fratricide—a phenomenon where activated NK cells kill each other due to the upregulation of CD70—CRISPR/Cas9 technology is employed to knock out the endogenous CD70 gene. This therapeutic candidate is designed to treat CD70-positive malignancies, including acute myeloid leukemia (AML), renal cell carcinoma (RCC), and various solid tumors, by targeting both tumor cells and cancer-associated fibroblasts in the tumor microenvironment.
- Other names
- CD70 CAR-NK-IL15CD-70 CAR-NK-IL15CD 70 CAR-NK-IL15CD70-targeted CAR-NK cells with IL-15CD-70-targeted CAR-NK cells with IL-15CD 70-targeted CAR-NK cells with IL-15CD70 knockout CAR-NK cells with IL-15CD-70 knockout CAR-NK cells with IL-15CD 70 knockout CAR-NK cells with IL-15
02
Targets
CD70 (Cluster of Differentiation 70)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on CD70-directed CAR-NK cells with IL-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD70-directed CAR-NK cells with IL-15.